INGN at a glance
Inogen Inc (INGN, SEC CIK 1294133) filed its latest 10-K annual report on February 27, 2026, a 10-Q quarterly report on November 9, 2026, an 8-K current report on November 19, 2026 and Form 4 insider filings as recently as September 3, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Inogen Inc (INGN) reported revenue of $295.3 million (up 5.9% from FY2024) and a net loss of $22.7 million. Diluted EPS was -$0.86.
- As of September 30, 2026, 25 institutional investment managers tracked by SignalX reported holding Inogen Inc (INGN) shares worth $44.3 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Yi Boyer Jennifer M on July 1, 2026 of 10,938 shares at $6.60 per share.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $295.3M
- +5.9% vs prior year
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 25 funds
- $44.3M · +0 vs prior quarter
- Latest 8-K
- Nov 19, 2026
- Item 5.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Management Discussion & Analysis
- Revenue $77.2M, down 2.4% YoY from $79.1M, with U.S. sales up 3.8% and international sales down 9.0%
- Gross margin 44.1% vs 45.7% YoY; continuing-operations loss $14.8M vs $3.6M, including $10.6M goodwill impairment
- Best market: U.S. sales $42.2M, up 3.8%; weakest: international sales $34.9M, down 9.0%
- Cash $81.8M plus marketable securities $15.0M; operating cash use $13.6M through nine months, share repurchases $11.2M
- Rental-business sale up to $24.8M; cost program targeting $20M annualized savings, with supply-chain, inflation, geopolitical, and freight headwinds
Risk Factors
- New divestiture risk triggered by November 2 Rental Business sale: Rotech consideration up to $24.8 million payable in six installments
- Regulatory and compliance risk: patient transfers require HIPAA, state privacy, and payor compliance
- Operational risk: Rental Business revenue of $35.6 million eliminated, increasing dependence on product sales
- Cost-reduction risk triggered by November 5 program: approximately $20 million annualized savings may not materialize
- Financial risk: retained Rental Business liabilities include potential Medicare, Medicaid, and payor recoupment demands
AI summary of the INGN 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Kevin R.M. Smith resigned as director effective November 16, 2026, following his October 30 officer and employee departure
- Separation terms include severance, prorated fiscal 2026 bonus eligibility based on actual performance, and December 1, 2026 equity vesting
Item 2.01: Completion of Acquisition or Disposition of Assets
- Completed sale of U.S. oxygen rental business to Rotech on November 2, 2026
- Assets transferred: specified on-rent and on-hand inventory plus related patient records
Item 2.02: Results of Operations and Financial Condition
- Q3 2026 results for quarter ended September 30, 2026, announced November 5, 2026
- Press release includes update on completed sale of Inogen’s U.S. rental business
Item 7.01: Regulation FD Disclosure
- Press release announces completion of Inogen’s previously disclosed U.S. rental business sale
- Transaction marks exit from the U.S. rental business, affecting revenue mix and operating strategy
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Andy Reding appointed President, CEO and Class III director through 2029, replacing Kevin Smith effective October 30, 2026
- No COO successor planned, concentrating operating responsibilities under the new CEO
Item 8.01: Other Events
- Board proposing annual director elections, replacing the classified board structure at the 2027 annual meeting
- Charter declassification previously won over 99% of votes cast, but failed the 66 2/3% outstanding-share threshold
Item EX-99.1: Item EX-99.1
- COO Andy Reding appointed President, CEO, and director, succeeding Kevin Smith
- Leadership change signals Board push to improve execution and restore sustainable, profitable growth
Item EX-99.2: Item EX-99.2
- Q3 revenue $77.2M, down 2.4% YoY, with U.S. growth 3.8% offset by international sales weakness
- Adjusted loss $0.4M versus $1.2M earnings, while GAAP loss widened to $14.8M, including a $10.6M impairment charge
Item 7.01: Regulation FD Disclosure
- Press release announces a Purchase Agreement with Rotech Healthcare Inc
- Separate product supply agreement with Rotech, creating an ongoing commercial relationship
Item 8.01: Other Events
- Repurchase authorization would rise from $30.0 million to $45.0 million upon Transaction closing
- Authorization extension through June 30, 2028, from December 31, 2027
Item 1.01: Entry into a Material Definitive Agreement
- Inogen selling substantially all U.S. oxygen rental business assets to Rotech Healthcare
- Purchase price up to approximately $24.8 million, subject to post-closing reconciliation
Item EX-99.1: Item EX-99.1
- Divestiture of U.S. oxygen rental assets to Rotech for estimated cash consideration up to $25 million, expected closing Q4 2026
- Rental Business generated $24.3 million revenue in H1 2026, down 9.8% year over year
AI summaries of INGN 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for INGN
Don't miss the next INGN filing
- Alerts as it files. A push when INGN files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut INGN, by share count.
- Ask anything. An AI agent that reads every INGN filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Wright Mary E | A | Sep 1, 2026 | 1,500 | $5.33 |
| Smith Kevin P. | A | Sep 1, 2026 | 1,500 | $5.33 |
| Smith Kevin P. | M | Sep 1, 2026 | 18,136 | - |
| Smith Kevin Raymond Merrill | A | Sep 1, 2026 | 1,500 | $5.33 |
| Smith Kevin P. | F | Sep 1, 2026 | 8,671 | $5.33 |
| Smith Kevin P. | M | Sep 1, 2026 | 18,136 | - |
| Reding Andrew P. | A | Jul 6, 2026 | 130,000 | - |
| Yi Boyer Jennifer M | Sell | Jul 1, 2026 | 10,938 | $6.60 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $278.8M | $295.3M |
| Gross Profit | - | $154.7M | $154.3M |
| Operating Income | - | -$42.5M | -$30.2M |
| Net Income | - | -$35.9M | -$22.7M |
| Gross Margin | - | 55.5% | 52.2% |
| Op. Margin | - | -15.3% | -10.2% |
| Net Margin | - | -12.9% | -7.7% |
| Balance Sheet | |||
| Total Assets | $326.2M | $296.2M | $298.6M |
| Equity | $204.8M | $173.9M | $192.2M |
| ROE | - | -20.6% | -11.8% |
| Per Share | |||
| EPS | - | $-1.52 | $-0.86 |
| Cash Flow | |||
| Operating CF | - | $5.9M | -$11.2M |
| CapEx | - | $3.4M | $2.5M |
Source: XBRL data in Inogen Inc (INGN)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate INGN share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 25 | $44.3M |
| Q2 2026 | 25 | $58.2M |
| Q1 2026 | 25 | $52.2M |
| Q4 2025 | 23 | $60.1M |
| Q3 2025 | 23 | $76.3M |
| Q2 2025 | 23 | $67.6M |
| Q1 2025 | 20 | $56.0M |
| Q4 2024 | 19 | $50.8M |
- JPMorgan Chase & Co+199.6K (+42%)
- Goldman Sachs Group+122.7K (+28%)
- D.E. Shaw & Co+80.7K (+217%)
- Morgan Stanley+45.3K (+7%)
- Millennium Management+6.9K (+29%)
- Ameriprise Financial−874.0K (-89%)
- AQR Capital Management−282.7K (-30%)
- Prudential Financial−161.8K (-49%)
- Dimensional Fund Advisors−32.8K (-7%)
- Wells Fargo & Co−15.9K (-77%)
- Citadel Advisors LLC+323.0K
- FMR LLC (Fidelity)−17.4K
Source: 13F-HR filings on SEC EDGAR (aggregated from 183 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
INGN filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 8-K | Nov 19, 2026 | - | Analysis | - |
| 10-Q | Nov 9, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Nov 5, 2026 | - | Analysis | - |
| 8-K | Sep 30, 2026 | - | Analysis | - |
| 4 | Sep 3, 2026 | - | - | - |
| 4 | Sep 3, 2026 | - | - | - |
| 4 | Sep 3, 2026 | - | - | - |
| 10-Q | Aug 7, 2026 | Jun 30, 2026 | - | |
| 8-K | Aug 6, 2026 | - | Analysis | - |
| 4 | Jul 9, 2026 | - | - | - |
| 4 | Jul 6, 2026 | - | - | - |
| 8-K | Jul 1, 2026 | - | Analysis | - |
| 8-K | Jun 11, 2026 | - | Analysis | - |
| 4 | Jun 9, 2026 | - | - | |
| 4 | Jun 9, 2026 | - | - | |
| 4 | Jun 9, 2026 | - | - | |
| 4 | Jun 9, 2026 | - | - | |
| 4 | Jun 9, 2026 | - | - | |
| 4 | Jun 9, 2026 | - | - | |
| 4 | Jun 9, 2026 | - | - | |
| 4 | Jun 2, 2026 | - | - | |
| 10-Q | May 8, 2026 | Mar 31, 2026 | - | |
| 8-K | May 7, 2026 | - | Analysis | |
| 4 | Apr 8, 2026 | - | - | - |
| 8-K | Apr 6, 2026 | - | Analysis | - |
Related Health Care companies
- ALGN · Align TechnologyOrthopedic, Prosthetic & Surgical Appliances & Supplies
- AVR · Anteris Technologies Global Corp.Orthopedic, Prosthetic & Surgical Appliances & Supplies
- AVNS · AVANOS MEDICAL, INC.Orthopedic, Prosthetic & Surgical Appliances & Supplies
- EW · Edwards LifesciencesOrthopedic, Prosthetic & Surgical Appliances & Supplies
- ENOV · Enovis CORPOrthopedic, Prosthetic & Surgical Appliances & Supplies
- ISRG · Intuitive SurgicalOrthopedic, Prosthetic & Surgical Appliances & Supplies
- LAKE · LAKELAND INDUSTRIES INCOrthopedic, Prosthetic & Surgical Appliances & Supplies
- MYO · MYOMO, INC.Orthopedic, Prosthetic & Surgical Appliances & Supplies
INGN SEC filings: frequently asked questions
Which institutions hold INGN stock?
As of September 30, 2026, the largest Inogen Inc (INGN) holders among the 13F filers tracked by SignalX were BlackRock ($9.2 million), Vanguard Capital Management LLC ($5.5 million), JPMorgan Chase & Co ($3.7 million), Morgan Stanley ($3.6 million), AQR Capital Management ($3.5 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was INGN's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Inogen Inc (INGN) reported revenue of $295.3 million (up 5.9% from FY2024) and a net loss of $22.7 million. Diluted EPS was -$0.86. The figures come from the XBRL data in the 10-K.
What did INGN report in its latest 8-K?
Inogen Inc (INGN) filed an 8-K on November 19, 2026 reporting Item 5.02 (Departure/Appointment of Directors or Principal Officers). Kevin R.M. Smith resigned as director effective November 16, 2026, following his October 30 officer and employee departure.
What are the latest INGN SEC filings?
Inogen Inc (INGN) filed its latest 10-K annual report on February 27, 2026, a 10-Q quarterly report on November 9, 2026, an 8-K current report on November 19, 2026 and a Form 4 insider filing on September 3, 2026.
What is INGN's SEC CIK number?
Inogen Inc (INGN)'s SEC Central Index Key (CIK) is 1294133. EDGAR lists every INGN filing under that number.
Ask anything about INGN
The research agent reads INGN's filings, financials, insider trades and 13F holders, then answers with sources.